Lina Khan, FTC chair (Graeme Sloan/Sipa USA)(Sipa via AP Images)

Did the FTC have a good rea­son to block the Sanofi-Maze deal?

Walls of redac­tions in the Fed­er­al Trade Com­mis­sion com­plaint tar­get­ing Sanofi’s deal with Maze Ther­a­peu­tics hold a vi­tal ques­tion for the bio­phar­ma in­dus­try: Was there a smok­ing gun show­ing Sanofi en­gaged in an­ti­com­pet­i­tive be­hav­ior?

The FTC com­plaint im­plies — but doesn’t pub­licly show — the an­swer. An­titrust ex­perts in­ter­viewed by End­points News said that what seems like a sur­pris­ing ac­tion was pack­aged in a more con­ven­tion­al le­gal the­o­ry than an ear­li­er FTC at­tempt to block a phar­ma­ceu­ti­cal deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.